Zhejiang Benli Technology Co., Ltd. Class A

Zhejiang Benli Technology Co., Ltd. Class A

SSZSE:301065
17.34
CNY
-0.17
(-0.97%)
0.79EPS
25.46P/E
2.13BMarket Cap
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
TTM
Revenue per Share
4.74
5.53
7.04
7.86
7.17
7.1
6.56
6.81
6.16
6.36
Basic EPS, GAAP
0.35
0.57
0.92
1.15
0.63
0.56
0.56
0.62
0.76
0.79
Free Cash Flow per Basic Share
0.03
0.48
-0.52
0.1
-0.16
-0.83
0.26
1.26
0.4
- -
Dividend per Share
0.06
0.19
0.02
0.03
0.02
0.23
0.1
0.1
0.2
- -
Book Value per Share
3.45
3.84
4.76
5.96
11.43
11.76
12.23
12.28
12.92
13.48
Tangible Book Value per Share
2.91
3.32
4.4
5.6
11.17
10.61
11.1
11.18
11.85
12.43
Basic Weighted Avg Shares
71
79
79
80
87
107
106
104
104
104
Sales/Revenue/Turnover
337
438
559
625
621
759
698
709
639
662
Operating Margin (%)
10.2
12.36
14.93
17.15
9.3
6.79
8.07
8.76
12.26
13.97
Depreciation Expense
23
23
25
32
39
49
53
58
63
- -
Net Income, GAAP
25
45
73
92
55
60
60
65
79
82
Effective Tax Rate (%)
15.67
11.75
11.97
13.35
11.48
9.78
9.89
13.83
12.37
12.83
Profit Margin (%)
7.46
10.24
13.07
14.68
8.83
7.88
8.54
9.11
12.35
12.39
Working Capital
69
50
124
105
775
684
718
689
713
673
LT Debt
30
- -
45
22
1
- -
- -
11
- -
- -
Total Equity
274
306
379
473
1,212
1,247
1,296
1,302
1,370
1,429
Return on Invested Capital (%)
- -
14.58
20.23
19.15
6.08
4.79
4.69
4.99
5.91
5.88
Return on Capital (%)
- -
17.73
22.54
20.06
6.51
4.88
4.75
4.95
5.89
5.91
Return on Common Equity (%)
- -
15.48
21.37
21.52
6.51
4.87
4.69
4.97
5.9
5.95

Capital Structure

CNY

•

in mil. unless spec.
Mar'26
Jun'26
Sep'26
ST Debt
1
1
1
LT Borrowings
- -
- -
- -
LT Finance Leases
- -
- -
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
106
106
106
Market Capitalization
2,412
1,871
2,127

Working Capital

CNY

•

in mil. unless spec.
Mar'26
Jun'26
Sep'26
Total Current Assets
928
913
902
Cash, Cash Equivalents & STI
628
563
633
Accounts Receivable, Net
132
135
101
Inventories
105
108
100
Total Current Liabilities
205
229
228
Payables & Accruals
- -
- -
- -
ST Debt
1
1
1
Deferred Revenue
- -
- -
- -

Growth Rates

CNY

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
- -
33.69%
5.22%
Free Cash Flow
- -
86.78%
-68.68%
Net Income, GAAP
- -
-0.21%
22.08%
Sales/Revenue/Turnover
- -
1.04%
-9.92%
Total Cash Common Dividend
- -
239.05%
99.4%

Quarterly Revenue

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
188
191
160
170
709
2025
162
180
- -
157
639
2026
162
208
134
- -
- -

Quarterly Earnings Per Share

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
0.16
0.24
0.09
0.14
0.62
2025
0.15
0.29
- -
0.22
0.76
2026
0.1
0.33
0.14
- -
- -

Quarterly Dividends Per Share

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
0.1
2025
- -
- -
- -
- -
0.2
2026
- -
- -
- -
- -
- -

Company Description

CEO
Zheng Jie Wu
Full Time Employees
588
Sector
Health technology
Industry
Pharmaceuticals: major
Address
Linhai China
IPO Date
Sep 14, 2021
Business
Zhejiang Benli Technology Co., Ltd. is a China-based fine chemical manufacturing enterprise engaged in the research, development, production, and commercialization of advanced pharmaceutical intermediates, agrochemical intermediates, and specialty chemical materials. The company operates primarily through three business segments: Pharmaceutical Intermediates, Agrochemical Intermediates, and Specialty Chemical Products. Its core product portfolio comprises quinolone antibacterial drug intermediates, including ethyl 2,4-dichloro-5-fluorobenzoylacetate (Product 801), ethyl 2-(2,4-dichloro-5-fluorobenzoyl)-3-cyclopropylaminoacrylate (Product 1201), cyclopropylamine, and cyclopropanecarboxylic acid derivatives utilized in the synthesis of fluoroquinolones such as ciprofloxacin, levofloxacin, enrofloxacin, and moxifloxacin; pesticide intermediates, including halogenated and heterocyclic compounds, pyrazole derivatives, and fluorinated benzene intermediates for fungicides, insecticides, and herbicides; and specialty functional chemicals, including cyclopropane series derivatives, aromatic fluorochemicals, and custom chemical building blocks for pharmaceutical synthesis and advanced materials. Zhejiang Benli Technology Co., Ltd. serves pharmaceutical formulation developers, active pharmaceutical ingredient (API) manufacturers, agrochemical producers, and fine chemical distributors across domestic Chinese markets and international regions throughout Asia, Europe, and the Americas. Founded in 2011 and headquartered in Taizhou, Zhejiang Province, China, the company maintains modernized manufacturing facilities, research and development centers, and operating subsidiaries across regional industrial parks. In recent operational developments, the company has advanced the construction and commissioning of green continuous-flow and microchannel synthesis production lines, expanded its capacity for high-value fluorinated and cyclopropane-based intermediates, broadened its custom development and manufacturing (CDMO) services, and deepened strategic supply alliances with leading domestic and multinational crop science and pharmaceutical enterprises to diversify its downstream commercial offerings.